Literature DB >> 15041727

Overexpression and amplification of Aurora-A in hepatocellular carcinoma.

Yung-Ming Jeng1, Shian-Yang Peng, Chiao-Ying Lin, Hey-Chi Hsu.   

Abstract

PURPOSE: Aurora-A/STK15/BTAK, a centrosome-associated serine/threonine kinase, has been shown to induce chromosomal instability, leading to aneuploidy and cell transformation. The purpose of this study was to investigate the expression and amplification of Aurora-A in hepatocellular carcinoma (HCC). EXPERIMENTAL
DESIGN: Aurora-A mRNA levels were measured in 224 HCCs and 199 paired nontumorous liver tissues by reverse transcription-PCR. Aurora-A mRNA and protein levels of 8 were also measured by reverse transcription-PCR and Western blot hybridization in 8 liver cancer cell lines. Amplification of Aurora-A was determined by Southern blot hybridization in 99 cases.
RESULTS: Aurora-A was overexpressed in 137 of 224 (61%) HCCs and all 8 of the cell lines. Overexpression of Aurora-A was associated with high-grade (grade II-IV), and high-stage (stage IIIB-IV) tumors, p53 mutation, infrequent beta-catenin mutation, and poor outcome. Aurora-A overexpression and p53 mutation acted synergistically toward poor prognosis. Amplification of Aurora-A was detected only in 3 HCCs.
CONCLUSION: The results show that Aurora-A is overexpressed frequently in HCC, and correlated with high grade and high stage, indicating that overexpression of Aurora-A plays a role in the development and progression of HCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15041727     DOI: 10.1158/1078-0432.ccr-1057-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  120 in total

Review 1.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

2.  Mantle cell lymphoma harboring Burkitt's-like translocations presents differential expression of aurora kinase genes compared with others 8q abnormalities.

Authors:  Fábio Morato de Oliveira; Ana Paula Nunes Rodrigues-Alves; Antônio Roberto Lucena-Araújo; Ferdinando de Paula Silva; Fernanda Borges da Silva; Roberto Passetto Falcão
Journal:  Med Oncol       Date:  2014-03-29       Impact factor: 3.064

3.  Suppression of Aurora-A oncogenic potential by c-Myc downregulation.

Authors:  Shangbin Yang; Shun He; Xiaobo Zhou; Mei Liu; Hongxia Zhu; Yihua Wang; Wei Zhang; Shuang Yan; Lanping Quan; Jingfeng Bai; Ningzhi Xu
Journal:  Exp Mol Med       Date:  2010-11-30       Impact factor: 8.718

Review 4.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

5.  Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target.

Authors:  Daniel Humme; Ahmed Haider; Markus Möbs; Hiroshi Mitsui; Mayte Suárez-Fariñas; Hanako Ohmatsu; Cyprienne Isabell Geilen; Jürgen Eberle; James G Krueger; Marc Beyer; Michael Hummel; Ioannis Anagnostopoulos; Wolfram Sterry; Chalid Assaf
Journal:  J Invest Dermatol       Date:  2015-04-07       Impact factor: 8.551

6.  A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells.

Authors:  Qiaohua Zhu; Meihua Luo; Chengyu Zhou; Zhiwei Zhou; Zhixu He; Xinfa Yu; Shufeng Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

7.  Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxia and HIF-1.

Authors:  Alexandra Klein; Daniela Flügel; Thomas Kietzmann
Journal:  Mol Biol Cell       Date:  2008-06-18       Impact factor: 4.138

8.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

9.  Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC.

Authors:  Zhong-Zhe Lin; Yung-Ming Jeng; Fu-Chang Hu; Hung-Wei Pan; Hsin-Wei Tsao; Po-Lin Lai; Po-Huang Lee; Ann-Lii Cheng; Hey-Chi Hsu
Journal:  BMC Cancer       Date:  2010-08-28       Impact factor: 4.430

10.  Aurora-A overexpression enhances cell-aggregation of Ha-ras transformants through the MEK/ERK signaling pathway.

Authors:  Ya-Shih Tseng; Jenq-Chang Lee; Chi-Ying F Huang; Hsiao-Sheng Liu
Journal:  BMC Cancer       Date:  2009-12-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.